Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

IOFINA PLC Board/Management Information 2018

Nov 16, 2018

7716_rns_2018-11-16_c4dd6da2-3b81-4755-8397-061a06951407.html

Board/Management Information

Open in viewer

Opens in your device viewer

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 5510H

Iofina PLC

16 November 2018

16 November 2018

Iofina Plc

("Iofina" or "the Company")

(LSE AIM: IOF)

Director Appointment

Iofina, specialists in the exploration and production of iodine and halogen-based specialty chemical derivatives, is pleased to announce the appointment of Frank Mermoud as a Non-Executive Director to the Company with immediate effect. 

Mr. Mermoud has more than 30 years' experience in international business, facilitating trade and investment in both the public and private sectors. He has held senior international, economic and commercial policy positions within the United States Government having served as the Secretary of State's Special Representative for Commercial and Business Affairs at U.S. Department of State from 2002 to 2009. Mr. Mermoud is also a Non-Executive Director of Cub Energy Inc. an oil and gas company headquartered in Houston, Texas and Chairman of Precision Risk and Intelligence Limited a due diligence and risk mitigation company based in the UK.

Commenting on the news, President and CEO Dr. Tom Becker, stated: "We are delighted to welcome Frank to the Board. Frank has a significant amount of international business and commercial experience through his time with the US Government, and throughout his career, and we look forward to him contributing his skills and knowledge to Iofina's growth plans. As a Non-Executive Director he will bring enhanced corporate governance and oversight to the Company as it continues to grow."

Enquiries:

Dr. Tom Becker, CEO & President

Iofina plc

Tel: +44 (0)20 3006 3135

Christopher Raggett/Giles Rolls/Antony Adams

finnCap Ltd

Tel: +44 (0)20 7220 0500

Media Contact:

Charles Goodwin/Harriet Jackson

Yellow Jersey PR Limited

Tel: +44 (0)7544 275 882

About Iofina:

Iofina specialises in the exploration and production of iodine, halogen based specialty chemical derivatives and produced water. Iofina's business strategy is to identify, develop, build, own and operate iodine extraction plants currently focused in North America, based on Iofina's WET® IOsorb® technology. Iofina has production operations in the United States, specifically in Kentucky and Oklahoma. It is a vertically integrated company, covering the process from the production of iodine in the field, to the manufacture of the chemical end-products derived from iodine, supplying them to the consumer, and the recycling of iodine using iodinated side-streams from waste chemical processes. Iofina utilises its portfolio of patented and patent-pending technology, and proprietary methods and trademarks throughout all business lines.

www.iofina.com

Additional information on Frank Mermoud:

The following information is disclosed in accordance with Schedule 2(g) of the AIM Rules for Companies.

Full name: Jules Frank (Frank) Mermoud

Age: 62

Shares in the Company held: None

Directorships/partnerships held in the last five years:

Current Past
Cub Energy Inc.

Precision Risk and Intelligence Limited

SCI Orpheus
None

Mr. Mermoud is also the sole shareholder and president (non-board) of Orpheus International Inc.

There are no other matters which are required to be announced for Frank Mermoud pursuant to Schedule 2(g) of the AIM Rules for Companies.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

END

BOABABBTMBIBTIP